Stocks · News reference
Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $667.470 million-$714.310 million to $667.470 million-$714.310 million vs $673.750 million estimate.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures
The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same